On Monday, El Pollo LoCo Holdings Inc (NASDAQ:LOCO)’s shares declined -0.69% to $18.80.
El Pollo Loco (LOCO), the nation’s leading fire-grilled chicken chain, declared the launch of their new line of $5 Pollo Bowl Combos. The four new Pollo Bowls are a fresh take on the popular Original Pollo Bowl(R) and feature El Pollo Loco’s famous citrus-marinated, fire-grilled chicken in the new Chicken & Shrimp, Mexican Caesar, Ranchero and Power bowl options.
El Pollo Loco Holdings, Inc., through its partner, El Pollo Loco, Inc., develops, franchises, licenses, and operates quick-service restaurants under the El Pollo Loco name in the United States. The company offers individual and family-sized chicken meals, Mexican-inspired entrees, sides, and, alternative proteins.
Lake Shore Gold Corp Ordinary Shares (NYSEMKT:LSG)’s shares dropped -3.83% to $0.880.
Lake Shore Gold Corp. (LSG) declared that the Company plans to release its first half and second quarter 2015 financial and operating results before the market opens on Thursday, July 30, 2015. The Company will then host a conference call to review the results later that day at 2:30 pm EST. Those wishing to access the call can do so using the telephone numbers listed below. The call will also be webcast and accessible on the Company’s website.
Lake Shore Gold Corp., a gold mining company, engages in the acquisition, exploration, and development of gold properties in Canada. It also explores for silver ores. The company’s principal properties comprise the Timmins West Complex, which covers an area of about 130 square kilometers located in Timmins, Ontario; Bell Creek Complex that covers an area of about 32 square kilometers situated in Timmins, Ontario; and Fenn-Gib, which comprises of 171 mining claims, patents, and leases covering about an area of 29 square kilometers. Lake Shore Gold Corp. was founded in 2002 and is headquartered in Toronto, Canada.
At the end of Monday’s trade, Medivation Inc (NASDAQ:MDVN)‘s shares dipped -1.28% to $111.80.
Medivation, Inc. ( MDVN) declared that it will host a live teleconference with administration to talk about second quarter 2015 financial results and provide a general business update on August 6, 2015 at 4:30 p.m. Eastern Time. A press release for the second quarter of 2015 will be released after markets close on August 6, 2015.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX), ended its Monday’s trading session with 2.72% gain, and closed at $63.44.
Pacira Pharmaceuticals, Inc. (PCRX) declared that Aratana Therapeutics, Inc. (PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs.
The randomized, blinded, multicenter pivotal study in dogs undergoing knee surgery demonstrated statistically noteworthy improvements in pain evaluation contrast to placebo at each of the 24-hour intervals up to 72 hours following surgery (P<0.05). Based on current timelines for the FDA approval process, Aratana anticipates startning commercialization of AT-003 in dogs in 2016.
acira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
